What is the treatment for urticaria?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Urticaria

The treatment of urticaria follows a stepwise approach, starting with standard-dose second-generation H1-antihistamines, increasing to up to 4 times the standard dose if needed, followed by omalizumab as add-on therapy for refractory cases, and cyclosporine as a third-line option. 1

First-Line Treatment

  • Second-generation H1-antihistamines are recommended as first-line treatment:
    • Fexofenadine 180mg
    • Cetirizine 10mg
    • Loratadine 10mg
    • Desloratadine
    • Bilastine
    • Levocetirizine 1

These medications are preferred over first-generation antihistamines due to their lower sedative effects. However, first-generation antihistamines may be useful for nighttime symptoms 1.

Stepwise Management Algorithm

Step 1: Standard-dose second-generation H1-antihistamines

  • Begin with standard dosing of a second-generation antihistamine
  • Monitor response using validated tools like Urticaria Control Test (UCT) and Urticaria Activity Score (UAS7) 1

Step 2: Up-dosing of antihistamines

  • If inadequate response to standard dose, increase to up to 4 times the standard dose
  • Example: Cetirizine 10mg → 40mg daily 1

Step 3: Add-on therapies for resistant cases

  • Omalizumab: 300mg every 4 weeks or 600mg every 2 weeks

    • FDA-approved for chronic spontaneous urticaria in adults and adolescents 12 years and older who remain symptomatic despite H1 antihistamine treatment
    • Monitor for anaphylaxis risk 1
  • Cyclosporine: Up to 5mg/kg body weight

    • Requires monitoring of blood pressure and renal function every 6 weeks
    • Potential risks: hypertension, epilepsy in predisposed individuals, hirsutism, gum hypertrophy, and renal failure 1
  • Additional options:

    • Leukotriene receptor antagonists (e.g., montelukast)
    • H2 antagonists (e.g., ranitidine) in combination with H1 antihistamines
    • Tacrolimus, mycophenolate mofetil, dapsone, sulfasalazine, tranexamic acid 1, 2

Special Considerations

Acute Urticaria with Anaphylaxis

If urticaria is accompanied by signs of anaphylaxis:

  1. Epinephrine 0.3 mg IM in the mid-antrolateral thigh as first-line treatment 1, 3
  2. Combined H1+H2 blockade (typically diphenhydramine 25-50 mg IV plus ranitidine 50 mg IV) 1
  3. Seek immediate emergency medical attention 1

Chronic Urticaria Management

  • Consider step-down only after at least 3 consecutive months of complete control
  • Reduce antihistamine dose gradually (not more than 1 tablet per month) 1
  • More than half of patients with chronic urticaria will have resolution or improvement of symptoms within one year 4, 2

Pediatric Patients

  • Use age-appropriate dosing of second-generation H1-antihistamines
  • Medication dosing must be weight-based
  • Food allergies are a common cause of urticaria in infants and may require evaluation by an allergist 1

Common Pitfalls and Caveats

  1. Trigger identification: Triggers can be identified in only 10-20% of patients with chronic urticaria, so don't delay treatment while searching for triggers 4, 2

  2. Overuse of corticosteroids: While brief corticosteroid bursts may be used as adjunctive treatment, long-term use should be avoided due to side effects 1, 2

  3. Limited laboratory workup: For chronic urticaria, only a simple laboratory workup is needed unless the history or physical examination suggests specific underlying conditions 4, 2

  4. Topical doxepin limitations: If used, should be limited to 8 days and 10% of body surface area (maximum 12g daily) due to risk of allergic contact dermatitis 1

  5. Monitoring disease control: Use validated tools like UCT and UAS7 to objectively assess treatment response rather than subjective reporting alone 1

References

Guideline

Chronic Urticaria Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Acute and Chronic Urticaria: Evaluation and Treatment.

American family physician, 2017

Research

Urticaria: evaluation and treatment.

American family physician, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.